Only losing 1 pound a week on semaglutide — what's going on?

You're three months in and still waiting for the bigger numbers to show up

You've been at it for a while. The nausea from the first few weeks has faded. You're eating less without really trying. And yet the scales are moving at a pace that feels underwhelming, a pound here, maybe two some weeks, nothing the next. It's a question our prescribers hear regularly, and it deserves a straight answer rather than reassurance that goes nowhere.

The first thing to check is which dose you are currently on. Semaglutide for weight management starts at 0.25 mg and is titrated upward, typically in four-weekly steps, through 0.5 mg, 1.0 mg, 1.7 mg and up to 2.4 mg, the maintenance dose where most trial weight loss was recorded. At the lower rungs, the appetite-suppressing effect is present but modest. One pound a week at 0.5 mg or 1.0 mg is not a sign that the medicine is not working; it reflects the fact that you have not yet reached the dose the medicine is designed to work at. The semaglutide dosing schedule exists for tolerability, not for therapeutic effect at each individual step. Patience here has clinical reasoning behind it.

If you are already at 2.4 mg and have been for more than eight weeks, and one pound a week has been your consistent ceiling, that is a different conversation. The STEP 1 trial, published in the New England Journal of Medicine, recorded average weight loss of around 15% over 68 weeks at the 2.4 mg dose, but that is an average across a large trial population, not a guaranteed individual outcome. Some participants lost considerably more; some lost considerably less.

The biological reasons a plateau feels like failure but usually isn't

Weight loss almost never proceeds in a straight line. The body adapts. As fat mass falls, resting energy expenditure drops too, your metabolism requires fewer calories to run a lighter frame. This is not a dysfunction; it is physiology. Clinical researchers refer to it as adaptive thermogenesis, and it is one reason why the rate of loss documented in trials tends to slow after the first three to six months even when adherence is perfect.

Fluid shifts complicate the picture further. Week-to-week scale readings are affected by hydration, salt intake, hormonal cycles and bowel habits. A reading of 1 lb down on a Tuesday might be 2.5 lb down if you'd weighed on a Friday. Many people find it more informative to track a monthly trend rather than a weekly figure. The realistic weekly loss on Wegovy varies considerably by individual, and most clinicians would evaluate progress over a four-week block rather than a single data point.

Other factors that genuinely slow semaglutide's effect include insufficient protein intake (which matters because the medicine may reduce overall food intake without discriminating between protein and less useful calories), poor sleep, high stress, medications that affect weight, and underlying thyroid or metabolic conditions. None of these can be identified from the outside. A prescriber review is the right way to work through them, not a higher dose without clinical assessment, and not an assumption that the medicine has stopped working.

When one pound a week might signal something worth reviewing

There is a formal threshold built into clinical guidance. NICE's recommendation on semaglutide for weight management suggests that if a person has not lost at least 5% of their starting body weight after six months on the maintenance dose, continuing treatment should be reviewed. That is the clinical yardstick, not a weekly target. NICE Technology Appraisal TA875 sets this out in the context of specialist weight management services, but the same logic applies to prescriber-supervised private treatment: results over six months at the right dose are the meaningful measure.

If you are approaching that six-month mark on 2.4 mg and weekly progress has consistently been minimal, speak to your prescriber. They may want to check whether anything is counteracting the medicine, whether the dose has been tolerated but not fully effective, or whether a different approach is warranted. There is now also a 7.2 mg semaglutide pen approved by the MHRA for adults with a BMI of 30 or above, which may be an option for some people where the standard dose has not produced sufficient results, again, subject to clinical assessment.

For context on what the treatment landscape looks like across different medicines, our guide to losing weight on Wegovy covers trial data and real-world expectations in more depth. And if you are curious about how semaglutide compares to tirzepatide, the weight-loss treatment overview sets out the licensed options available in the UK.

What actually helps if progress is slower than you'd hoped

The practical levers matter here. Semaglutide reduces appetite but does not directly dictate what you eat in the space that creates. Adequate protein (most clinical dietitians suggest somewhere around 1.2–1.6 g per kg of body weight for people in a calorie deficit) helps preserve muscle mass and keeps satiety more stable between doses. Resistance exercise has a similar preserving effect. These are not magic additions, but they are the ones with the most consistent evidence behind them during GLP-1 treatment.

Consistency with the injection timing matters too. Semaglutide is a weekly medicine, and missed or late doses reduce the steady-state plasma concentration. If you are earlier in your treatment and want to understand when you can expect to start losing weight on semaglutide across the course of treatment, that is exactly the kind of question the aftercare support at nume is set up for. One pound a week may not be the end of the story. It is often just where the story is right now, and a quick check-in with your prescriber (before the 12pm cut-off on any weekday if you want a same-day response) is the most useful next step.

If you have not yet started treatment and are considering your options, checking your eligibility through a free consultation is a sensible place to begin.